-
1.发明申请公开(公告)号：US20120329093A1
公开(公告)日：2012-12-27
申请号：US13539534
申请日：2012-07-02
CPC分类号： C07K16/244 , A61K2039/505 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/52 , C07K2317/76 , C07K2317/92 , C07K2319/30 , G01N33/6869 , G01N2333/54 , Y10S530/809
摘要： The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.
摘要翻译： 本发明涉及阻断，抑制，降低，拮抗或中和IL-17A和IL-17F的活性。 IL-17A和IL-17F是参与炎症过程和人类疾病的细胞因子。 本发明包括结合IL-17A和IL-17F的抗体，产生抗体的杂交瘤，以及在炎症中使用该抗体的方法。
-
2.发明授权Antibodies that bind both IL-17A and IL-17F and methods of using the same 有权结合IL-17A和IL-17F的抗体及其使用方法公开(公告)号：US07790163B2
公开(公告)日：2010-09-07
申请号：US11741189
申请日：2007-04-27
IPC分类号： A61K39/395
CPC分类号： C07K16/244 , A61K2039/505 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/52 , C07K2317/76 , C07K2317/92 , C07K2319/30 , G01N33/6869 , G01N2333/54 , Y10S530/809
摘要： The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, an methods of using the same in inflammation.
摘要翻译： 本发明涉及阻断，抑制，降低，拮抗或中和IL-17A和IL-17F的活性。 IL-17A和IL-17F是参与炎症过程和人类疾病的细胞因子。 本发明包括结合IL-17A和IL-17F的抗体，产生抗体的杂交瘤，在炎症中使用该抗体的方法。
-
公开(公告)号：US08609099B2
公开(公告)日：2013-12-17
申请号：US12832311
申请日：2010-07-08
IPC分类号： A61K39/395
CPC分类号： C07K16/244 , A61K2039/505 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/52 , C07K2317/76 , C07K2317/92 , C07K2319/30 , G01N33/6869 , G01N2333/54 , Y10S530/809
摘要： The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.
摘要翻译： 本发明涉及阻断，抑制，减少，拮抗或中和IL-17A和IL-17F的活性。 IL-17A和IL-17F是参与炎症过程和人类疾病的细胞因子。 本发明包括结合IL-17A和IL-17F的抗体，产生抗体的杂交瘤，以及在炎症中使用该抗体的方法。
-
4.发明申请ANTIBODIES THAT BIND BOTH IL-17A AND IL-17F AND METHODS OF USING THE SAME 有权与IL-17A和IL-17F两个结合的抗体及其使用方法公开(公告)号：US20100310565A1
公开(公告)日：2010-12-09
申请号：US12832311
申请日：2010-07-08
IPC分类号： A61K39/395 , C07K16/24 , A61P19/02 , A61P11/06
CPC分类号： C07K16/244 , A61K2039/505 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/52 , C07K2317/76 , C07K2317/92 , C07K2319/30 , G01N33/6869 , G01N2333/54 , Y10S530/809
摘要： The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.
摘要翻译： 本发明涉及阻断，抑制，减少，拮抗或中和IL-17A和IL-17F的活性。 IL-17A和IL-17F是参与炎症过程和人类疾病的细胞因子。 本发明包括结合IL-17A和IL-17F的抗体，产生抗体的杂交瘤，以及在炎症中使用该抗体的方法。
-
5.发明申请ANTIBODIES THAT BIND BOTH IL-17A AND IL-17F AND METHODS OF USING THE SAME 有权与IL-17A和IL-17F两个结合的抗体及其使用方法公开(公告)号：US20090004199A1
公开(公告)日：2009-01-01
申请号：US11741189
申请日：2007-04-27
IPC分类号： A61K39/395 , C07K16/24 , A61P29/00 , G01N33/567 , C12N5/16 , A61P37/02 , C12N9/00
CPC分类号： C07K16/244 , A61K2039/505 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/52 , C07K2317/76 , C07K2317/92 , C07K2319/30 , G01N33/6869 , G01N2333/54 , Y10S530/809
摘要： The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, an methods of using the same in inflammation.
摘要翻译： 本发明涉及阻断，抑制，降低，拮抗或中和IL-17A和IL-17F的活性。 IL-17A和IL-17F是参与炎症过程和人类疾病的细胞因子。 本发明包括结合IL-17A和IL-17F的抗体，产生抗体的杂交瘤，在炎症中使用该抗体的方法。
-
6.发明申请ANTIBODIES THAT BIND BOTH IL-17A AND IL-17F AND METHODS OF USING THE SAME 审中-公开与IL-17A和IL-17F两个结合的抗体及其使用方法公开(公告)号：US20120177653A1
公开(公告)日：2012-07-12
申请号：US13364810
申请日：2012-02-02
IPC分类号： A61K39/395 , A61P29/00 , C07K16/24
CPC分类号： C07K16/468 , A61K2039/505 , C07K16/244 , C07K2317/20 , C07K2317/24 , C07K2317/33 , C07K2317/52 , C07K2317/76
摘要： The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, as well as methods of using the same in inflammation.
摘要翻译： 本发明涉及阻断，抑制，降低，拮抗或中和IL-17A和IL-17F的活性。 IL-17A和IL-17F是参与炎症过程和人类疾病的细胞因子。 本发明包括结合IL-17A和IL-17F的抗体以及在炎症中使用它们的方法。
-
7.发明申请SOLUBLE ZCYTOR14, ANTI-ZCYTOR14 ANTIBODIES AND BINDING PARTNERS AND METHODS OF USING IN INFLAMMATION 有权可溶性ZCYTOR14抗体ZIYTOR14抗体和结合合作伙伴及其使用方法公开(公告)号：US20110177083A1
公开(公告)日：2011-07-21
申请号：US13015304
申请日：2011-01-27
申请人： Scott R. Presnell , Steven K. Burkhead , Steven D. Levin , Rolf E. Kuestner , Zeren Gao , Stephen R. Jaspers , Janine Bilsborough
发明人： Scott R. Presnell , Steven K. Burkhead , Steven D. Levin , Rolf E. Kuestner , Zeren Gao , Stephen R. Jaspers , Janine Bilsborough
IPC分类号： A61K39/395 , A61K38/17 , A61P25/28
CPC分类号： C07K16/2866 , A61K2039/505 , C07K14/7155 , C07K2317/73 , C07K2317/76 , C07K2319/30
摘要： The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17F, IL-17A, or both IL-17A and IL-17F polypeptide molecules. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. ZcytoR14 is a common receptor for IL-17A and IL-17F. The present invention includes soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners, as well as methods for antagonizing IL-17F, IL-17A or both IL-17A and IL-17F using such soluble receptors, antibodies and binding partners.
摘要翻译： 本发明涉及阻断，抑制，降低，拮抗或中和IL-17F，IL-17A或IL-17A和IL-17F两者多肽分子的活性。 IL-17A和IL-17F是参与炎症过程和人类疾病的细胞因子。 ZcytoR14是IL-17A和IL-17F的常见受体。 本发明包括可溶性ZcytoR14，抗ZcytoR14抗体和结合配偶体，以及使用这种可溶性受体，抗体和结合配偶体拮抗IL-17F，IL-17A或IL-17A和IL-17F两者的方法。
-
8.发明申请METHODS OF INHIBITING INFLAMMATION WITH ANTAGONISTS TO IL-17A, IL-17F, AND IL-23P19 有权用IL-17A，IL-17F和IL-23P19抑制炎症反应的方法公开(公告)号：US20110159589A1
公开(公告)日：2011-06-30
申请号：US13032501
申请日：2011-02-22
申请人： Katherine E. Lewis , Scott R. Presnell , Steven D. Levin , George Robert Mabry, III , Stephen R. Jaspers , Monica J. Huber
发明人： Katherine E. Lewis , Scott R. Presnell , Steven D. Levin , George Robert Mabry, III , Stephen R. Jaspers , Monica J. Huber
IPC分类号： C12N5/02
CPC分类号： C07K16/244 , A61K2039/505 , A61K2039/507 , C07K2317/14 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2317/92 , Y10S530/809
摘要： The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
摘要翻译： 本发明涉及阻断，抑制，降低，拮抗或中和IL-17A，IL-17F和IL-23的活性。 拮抗剂包括结合IL-23并结合IL-17A或IL-17F的抗体和抗体片段，例如IL-17A和IL-17F交叉反应的抗体。 还公开了包括结合IL-23的抗体或抗体片段和在一个分子上结合IL-17A或IL-17F的抗体或抗体片段的拮抗剂。 还公开了结合IL-23和IL-17F但不结合IL-17A的抗体和抗体片段。 IL-17和IL-23是涉及炎症过程和人类疾病的细胞因子。
-
9.发明授权公开(公告)号：US07910703B2
公开(公告)日：2011-03-22
申请号：US12111117
申请日：2008-04-28
申请人： Katherine E. Lewis , Scott R. Presnell , Steven D. Levin , George Robert Mabry, III , Stephen R. Jaspers , Monica J. Huber
发明人： Katherine E. Lewis , Scott R. Presnell , Steven D. Levin , George Robert Mabry, III , Stephen R. Jaspers , Monica J. Huber
IPC分类号： C12P21/08
CPC分类号： C07K16/244 , A61K2039/505 , A61K2039/507 , C07K2317/14 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2317/92 , Y10S530/809
摘要： The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
摘要翻译： 本发明涉及阻断，抑制，降低，拮抗或中和IL-17A，IL-17F和IL-23的活性。 拮抗剂包括结合IL-23并结合IL-17A或IL-17F的抗体和抗体片段，例如IL-17A和IL-17F交叉反应的抗体。 还公开了包括结合IL-23的抗体或抗体片段和在一个分子上结合IL-17A或IL-17F的抗体或抗体片段的拮抗剂。 还公开了结合IL-23和IL-17F但不结合IL-17A的抗体和抗体片段。 IL-17和IL-23是涉及炎症过程和人类疾病的细胞因子。
-
10.发明申请ANTAGONISTS TO IL-17A, IL-17F, AND IL-23P19 AND METHODS OF USE 有权对IL-17A，IL-17F和IL-23P19的拮抗作用及其使用方法公开(公告)号：US20080299129A1
公开(公告)日：2008-12-04
申请号：US12111117
申请日：2008-04-28
申请人： Katherine E. Lewis , Scott R. Presnell , Steven D. Levin , George Robert Mabry, III , Stephen R. Jaspers , Monica J. Huber
发明人： Katherine E. Lewis , Scott R. Presnell , Steven D. Levin , George Robert Mabry, III , Stephen R. Jaspers , Monica J. Huber
CPC分类号： C07K16/244 , A61K2039/505 , A61K2039/507 , C07K2317/14 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2317/92 , Y10S530/809
摘要： The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
摘要翻译： 本发明涉及阻断，抑制，降低，拮抗或中和IL-17A，IL-17F和IL-23的活性。 拮抗剂包括结合IL-23并结合IL-17A或IL-17F的抗体和抗体片段，例如IL-17A和IL-17F交叉反应的抗体。 还公开了包括结合IL-23的抗体或抗体片段和在一个分子上结合IL-17A或IL-17F的抗体或抗体片段的拮抗剂。 还公开了结合IL-23和IL-17F但不结合IL-17A的抗体和抗体片段。 IL-17和IL-23是涉及炎症过程和人类疾病的细胞因子。
-
-
-
-
-
-
-
-
-
搜索结果
154 条记录 (耗时 0.049 秒)
